-+ 0.00%
-+ 0.00%
-+ 0.00%

Lyon: The target price of Shengxinda Biotech (01801) will reach HK$139.9, and there will be overseas trade cooperation

Zhitongcaijing·07/16/2026 06:33:16
Listen to the news

The Zhitong Finance App learned that Lyon released a research report saying that Cinda Biotech (01801) announced on July 14 that it has authorized the rights of its immunological drug iBi355 outside of Greater China to Spero Therapeutics, with a total transaction amount of 1.1 billion US dollars. The bank believes that although the scale of this deal is smaller than the other two deals reached at the beginning of this year, the latest deal once again reflects Cinda Biotech's R&D strength. Lyon raised Cinda Biotech's target price from HK$135.8 to HK$139.9, maintaining the “outperforming the market” rating.